Amgen, Inc. Tumbles 11% as Pricing Concerns Mount for Lead Drug Enbrel

Amgen, Inc. Tumbles 11% as Pricing Concerns Mount for Lead Drug Enbrel


The stock, nonetheless, has fallen by as much as 11% in Friday's trading session, and the culprit appears to be none other than pricing power for its lead drug, Enbrel. For the quarter, Amgen reported a 2% increase in sales to $5.81 billion, with net product sales completely flat on a year-over-year basis at $5.52 billion.



from Biotech News